Related references
Note: Only part of the references are listed.Luteolin, quercetin and ursolic acid are potent inhibitors of proliferation and inducers of apoptosis in both KRAS and BRAF mutated human colorectal cancer cells
Cristina P. R. Xavier et al.
CANCER LETTERS (2009)
Role of Pharmacogenetics as Predictive Biomarkers of Response and/or Toxicity in the Treatment of Colorectal Cancer
Shriya Bhushan et al.
CLINICAL COLORECTAL CANCER (2009)
Clinical implications of microsatellite instability in sporadic colon cancers
Frank A. Sinicrope et al.
CURRENT OPINION IN ONCOLOGY (2009)
p38MAPK: stress responses from molecular mechanisms to therapeutics
Lydia R. Coulthard et al.
TRENDS IN MOLECULAR MEDICINE (2009)
Unmasking the role ofKRASandBRAFpathways in MSI colorectal tumors
Raquel Seruca et al.
Expert Review of Gastroenterology & Hepatology (2009)
Signal integration by JNK and p38 MAPK pathways in cancer development
Erwin F. Wagner et al.
NATURE REVIEWS CANCER (2009)
Natural Products and Colon Cancer: Current Status and Future Prospects
Subapriya Rajamanickam et al.
DRUG DEVELOPMENT RESEARCH (2008)
Cancer chemoprevention and chemotherapy: Dietary polyphenols and signalling pathways
Sonia Ramos
MOLECULAR NUTRITION & FOOD RESEARCH (2008)
BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAFV600E but not KRAS mutations
A. Preto et al.
JOURNAL OF PATHOLOGY (2008)
Cell death in response to antimetabolites directed at thymidylate synthase
Karen W. Barbour et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
The role of chemotherapy in microsatellite unstable (MSI-H) colorectal cancer
Janindra Warusavitarne et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2007)
Synergistic effect of triptolide combined with 5-fluorouracil on colon carcinoma
Xiao-yan Tang et al.
POSTGRADUATE MEDICAL JOURNAL (2007)
Luteolin sensitizes the anticancer effect of cisplatin via c-Jun NH2-terminal kinase-mediated p53 phosphorylation and stabilization
Ranxin Shi et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Rosiglitazone enhances fluorouracil-induced apoptosis of HT-29 cells by activating peroxisome proliferator-activated receptor-γ
Yan-Qin Zhang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2007)
Notoginseng enhances anti-cancer effect of 5-fluorouracil on human colorectal cancer cells
Chong-Zhi Wang et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Targeted molecular therapy of the PI3K pathway - Therapeutic significance of PI3K subunit targeting in colorectal carcinoma
Piotr G. Rychahou et al.
ANNALS OF SURGERY (2006)
Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer
R. Jover et al.
GUT (2006)
Molecular targets of dietary agents for prevention and therapy of cancer
BB Aggarwal et al.
BIOCHEMICAL PHARMACOLOGY (2006)
Microsatellite instability in colorectal cancer
K Söreide et al.
BRITISH JOURNAL OF SURGERY (2006)
Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery
N Thompson et al.
CURRENT OPINION IN PHARMACOLOGY (2005)
Role of JNK activation in apoptosis: A double-edged sword
J Liu et al.
CELL RESEARCH (2005)
PI3K-Akt pathway: Its functions and alterations in human cancer
M Osaki et al.
APOPTOSIS (2004)
Colon cancer: genomics and apoptotic events
C Rupnarain et al.
BIOLOGICAL CHEMISTRY (2004)
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer
CM Ribic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma
N Itoh et al.
CANCER (2002)
Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and Bcl-xL in addition to Bax and p53 status
S Violette et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Extensive characterization of genetic alterations in a series of human colorectal cancer cell lines
J Gayet et al.
ONCOGENE (2001)